Interações de agentes antifúngicos e antibacterianos frente a Cryptococcus neoformans antes e após indução capsular

Detalhes bibliográficos
Autor(a) principal: Rossato, Luana
Data de Publicação: 2013
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Manancial - Repositório Digital da UFSM
dARK ID: ark:/26339/0013000018jvx
Texto Completo: http://repositorio.ufsm.br/handle/1/5971
Resumo: The genus Cryptococcus consists of encapsulated yeasts that cause mainly cryptococcal meningoencephalitis in immunocompromised patients. This mycosis shows high percentage of morbidity and mortality. The fault is not the recommended therapeutic conveniently clarified and, concerning the susceptibility of the fungus to the antifungal, resistance detected in vitro is less frequent than the therapeutic failures. At this juncture, we discuss two aspects: a) considered the presence of the capsule in susceptibility testing, and b) evaluated combinations of conventional antifungal agents (amphotericin B, fluconazole and flucytosine) as well as associations of amphotericin B with antibacterial (azithromycin, daptomycin, linezolid, minocycline, tigecycline and trimethoprim) against 30 isolates of Cryptococcus neoformans. Susceptibility tests to each of the antimicrobial agents and the combinations were performed based on the protocol M27-A3 (CLSI, 2008), with adaptations to ensure the growth of the capsule. Combinations evaluated outside the model "checkerboard". The minimum inhibitory concentrations (MICs) of antifungal agents were higher outside the capsule group (Group II) than in the group without inducing capsular (group I); alone, antibacterials showed no antifungal activity groups studied. Among the combinations of antifungal drugs, showed that amphotericin B + flucytosine has been demonstrated that the highest percentage of synergism against encapsulated isolates (group II), which confirms what is observed in clinic. In the combinations of amphotericin B with antibacterial observed differences in activity: the group without inducing capsular (group I) amphotericin B +minocycline and amphotericin B + tigecycline showed higher percentages of synergism, in group II the best results of synergism were observed for combinations anfhotericin B+linezolid, and anfhotericin B+tigecycline.
id UFSM_8957aeed0758e46ccd29ce0735360410
oai_identifier_str oai:repositorio.ufsm.br:1/5971
network_acronym_str UFSM
network_name_str Manancial - Repositório Digital da UFSM
repository_id_str
spelling Interações de agentes antifúngicos e antibacterianos frente a Cryptococcus neoformans antes e após indução capsularInteractions of antifungal agents antibacterials front and a Cryptococcus neoformans before and after induction capsularCryptococcus spp.SusceptibilidadeCápsulaAssociaçõesAntifúngicosAntibacterianosCryptococcus spp.SusceptibilityCapsuleAssociationsAntifungalAntibacterialCNPQ::CIENCIAS DA SAUDE::FARMACIAThe genus Cryptococcus consists of encapsulated yeasts that cause mainly cryptococcal meningoencephalitis in immunocompromised patients. This mycosis shows high percentage of morbidity and mortality. The fault is not the recommended therapeutic conveniently clarified and, concerning the susceptibility of the fungus to the antifungal, resistance detected in vitro is less frequent than the therapeutic failures. At this juncture, we discuss two aspects: a) considered the presence of the capsule in susceptibility testing, and b) evaluated combinations of conventional antifungal agents (amphotericin B, fluconazole and flucytosine) as well as associations of amphotericin B with antibacterial (azithromycin, daptomycin, linezolid, minocycline, tigecycline and trimethoprim) against 30 isolates of Cryptococcus neoformans. Susceptibility tests to each of the antimicrobial agents and the combinations were performed based on the protocol M27-A3 (CLSI, 2008), with adaptations to ensure the growth of the capsule. Combinations evaluated outside the model "checkerboard". The minimum inhibitory concentrations (MICs) of antifungal agents were higher outside the capsule group (Group II) than in the group without inducing capsular (group I); alone, antibacterials showed no antifungal activity groups studied. Among the combinations of antifungal drugs, showed that amphotericin B + flucytosine has been demonstrated that the highest percentage of synergism against encapsulated isolates (group II), which confirms what is observed in clinic. In the combinations of amphotericin B with antibacterial observed differences in activity: the group without inducing capsular (group I) amphotericin B +minocycline and amphotericin B + tigecycline showed higher percentages of synergism, in group II the best results of synergism were observed for combinations anfhotericin B+linezolid, and anfhotericin B+tigecycline.Fundação de Amparo a Pesquisa do Estado de São PauloO gênero Cryptococcus é constituído por fungos leveduriformes encapsulados que causam principalmente meningoencefalite criptococócica em pacientes imunocomprometidos. Esta micose evidencia elevados percentuais de morbidade e mortalidade. As falhas às terapêuticas recomendadas não esta convenientemente esclarecidas e, no tocante a suscetibilidade do fungo aos antimicóticos, a resistência detectada in vitro é menos freqüente do que as falhas terapêuticas. Nesta conjuntura, abordaremos dois aspectos: a) considerou-se a presença da cápsula nos ensaios de suscetibilidade e, b) avaliou-se combinações entre antifúngicos convencionais (anfotericina B, fluconazol e flucitosina) bem como associações de anfotericina B com antibacterianos (azitromicina, daptomicina, linezolida, minociclina, tigeciclina e trimetropim) frente a 30 isolados de Cryptococcus neoformans. Os testes de suscetibilidade a cada um dos agentes antimicrobianos bem como às combinações foram realizadas com base no protocolo M27-A3 (CLSI, 2008), com adaptações para garantir o crescimento da cápsula. As combinações fora avaliadas pelo modelo checkerboard . As concentrações inibitórias mínimas (CIMs) dos antimicóticos foram mais elevadas frente ao grupo com cápsula (Grupo II) do que no grupo sem indução capsular (grupo I); isoladamente, os antibacterianos não evidenciaram atividade antifúngica aos grupos estudados. Entre as combinações de antifúngicos, observou-se que a anfotericina B+flucitosina foi a que evidenciou maior percentual de sinergismos frente aos isolados encapsulados (grupo II), o que confirma ao observado na clínica. Nas combinações de anfotericina B com antibacterianos observou-se diferenças de atividade: no grupo sem indução capsular (grupo I) anfotericina B+minociclina e anfotericina B+ tigeciclina evidenciaram maiores percentuais de sinergismo; no grupo II os melhores resultados de sinergismo foram observados pelas combinações anfotericina B+linezolida e anfotericina B+tigeciclina.Universidade Federal de Santa MariaBRFarmáciaUFSMPrograma de Pós-Graduação em Ciências FarmacêuticasAlves, Sydney Hartzhttp://lattes.cnpq.br/0330782478769631Severo, Cecília Bittencourthttp://lattes.cnpq.br/5316317805512946Santurio, Janio Moraishttp://lattes.cnpq.br/6316012260769979Rossato, Luana2015-02-092015-02-092013-07-18info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfapplication/pdfROSSATO, Luana. INTERACTIONS OF ANTIFUNGAL AGENTS ANTIBACTERIALS FRONT AND A Cryptococcus neoformans BEFORE AND AFTER INDUCTION CAPSULAR. 2013. 114 f. Dissertação (Mestrado em Farmacologia) - Universidade Federal de Santa Maria, Santa Maria, 2013.http://repositorio.ufsm.br/handle/1/5971ark:/26339/0013000018jvxporinfo:eu-repo/semantics/openAccessreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSM2022-10-19T15:19:30Zoai:repositorio.ufsm.br:1/5971Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/ONGhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.comopendoar:2022-10-19T15:19:30Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false
dc.title.none.fl_str_mv Interações de agentes antifúngicos e antibacterianos frente a Cryptococcus neoformans antes e após indução capsular
Interactions of antifungal agents antibacterials front and a Cryptococcus neoformans before and after induction capsular
title Interações de agentes antifúngicos e antibacterianos frente a Cryptococcus neoformans antes e após indução capsular
spellingShingle Interações de agentes antifúngicos e antibacterianos frente a Cryptococcus neoformans antes e após indução capsular
Rossato, Luana
Cryptococcus spp.
Susceptibilidade
Cápsula
Associações
Antifúngicos
Antibacterianos
Cryptococcus spp.
Susceptibility
Capsule
Associations
Antifungal
Antibacterial
CNPQ::CIENCIAS DA SAUDE::FARMACIA
title_short Interações de agentes antifúngicos e antibacterianos frente a Cryptococcus neoformans antes e após indução capsular
title_full Interações de agentes antifúngicos e antibacterianos frente a Cryptococcus neoformans antes e após indução capsular
title_fullStr Interações de agentes antifúngicos e antibacterianos frente a Cryptococcus neoformans antes e após indução capsular
title_full_unstemmed Interações de agentes antifúngicos e antibacterianos frente a Cryptococcus neoformans antes e após indução capsular
title_sort Interações de agentes antifúngicos e antibacterianos frente a Cryptococcus neoformans antes e após indução capsular
author Rossato, Luana
author_facet Rossato, Luana
author_role author
dc.contributor.none.fl_str_mv Alves, Sydney Hartz
http://lattes.cnpq.br/0330782478769631
Severo, Cecília Bittencourt
http://lattes.cnpq.br/5316317805512946
Santurio, Janio Morais
http://lattes.cnpq.br/6316012260769979
dc.contributor.author.fl_str_mv Rossato, Luana
dc.subject.por.fl_str_mv Cryptococcus spp.
Susceptibilidade
Cápsula
Associações
Antifúngicos
Antibacterianos
Cryptococcus spp.
Susceptibility
Capsule
Associations
Antifungal
Antibacterial
CNPQ::CIENCIAS DA SAUDE::FARMACIA
topic Cryptococcus spp.
Susceptibilidade
Cápsula
Associações
Antifúngicos
Antibacterianos
Cryptococcus spp.
Susceptibility
Capsule
Associations
Antifungal
Antibacterial
CNPQ::CIENCIAS DA SAUDE::FARMACIA
description The genus Cryptococcus consists of encapsulated yeasts that cause mainly cryptococcal meningoencephalitis in immunocompromised patients. This mycosis shows high percentage of morbidity and mortality. The fault is not the recommended therapeutic conveniently clarified and, concerning the susceptibility of the fungus to the antifungal, resistance detected in vitro is less frequent than the therapeutic failures. At this juncture, we discuss two aspects: a) considered the presence of the capsule in susceptibility testing, and b) evaluated combinations of conventional antifungal agents (amphotericin B, fluconazole and flucytosine) as well as associations of amphotericin B with antibacterial (azithromycin, daptomycin, linezolid, minocycline, tigecycline and trimethoprim) against 30 isolates of Cryptococcus neoformans. Susceptibility tests to each of the antimicrobial agents and the combinations were performed based on the protocol M27-A3 (CLSI, 2008), with adaptations to ensure the growth of the capsule. Combinations evaluated outside the model "checkerboard". The minimum inhibitory concentrations (MICs) of antifungal agents were higher outside the capsule group (Group II) than in the group without inducing capsular (group I); alone, antibacterials showed no antifungal activity groups studied. Among the combinations of antifungal drugs, showed that amphotericin B + flucytosine has been demonstrated that the highest percentage of synergism against encapsulated isolates (group II), which confirms what is observed in clinic. In the combinations of amphotericin B with antibacterial observed differences in activity: the group without inducing capsular (group I) amphotericin B +minocycline and amphotericin B + tigecycline showed higher percentages of synergism, in group II the best results of synergism were observed for combinations anfhotericin B+linezolid, and anfhotericin B+tigecycline.
publishDate 2013
dc.date.none.fl_str_mv 2013-07-18
2015-02-09
2015-02-09
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv ROSSATO, Luana. INTERACTIONS OF ANTIFUNGAL AGENTS ANTIBACTERIALS FRONT AND A Cryptococcus neoformans BEFORE AND AFTER INDUCTION CAPSULAR. 2013. 114 f. Dissertação (Mestrado em Farmacologia) - Universidade Federal de Santa Maria, Santa Maria, 2013.
http://repositorio.ufsm.br/handle/1/5971
dc.identifier.dark.fl_str_mv ark:/26339/0013000018jvx
identifier_str_mv ROSSATO, Luana. INTERACTIONS OF ANTIFUNGAL AGENTS ANTIBACTERIALS FRONT AND A Cryptococcus neoformans BEFORE AND AFTER INDUCTION CAPSULAR. 2013. 114 f. Dissertação (Mestrado em Farmacologia) - Universidade Federal de Santa Maria, Santa Maria, 2013.
ark:/26339/0013000018jvx
url http://repositorio.ufsm.br/handle/1/5971
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Santa Maria
BR
Farmácia
UFSM
Programa de Pós-Graduação em Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade Federal de Santa Maria
BR
Farmácia
UFSM
Programa de Pós-Graduação em Ciências Farmacêuticas
dc.source.none.fl_str_mv reponame:Manancial - Repositório Digital da UFSM
instname:Universidade Federal de Santa Maria (UFSM)
instacron:UFSM
instname_str Universidade Federal de Santa Maria (UFSM)
instacron_str UFSM
institution UFSM
reponame_str Manancial - Repositório Digital da UFSM
collection Manancial - Repositório Digital da UFSM
repository.name.fl_str_mv Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)
repository.mail.fl_str_mv atendimento.sib@ufsm.br||tedebc@gmail.com
_version_ 1815172472428822528